The second part of this series of two reviews describes some of the chronic functional consequences of treatment for childhood and adolescent malignancy including impairment of neuropsychological, metabolic and immunological function, growth and quality of life. In addition, the increased risk of secondary malignant neoplasms and of late yet still premature mortality, and the nature of late toxicity in survivors of CNS tumours and HSCTs, will be highlighted. The development of appropriate long-term follow-up strategies intended to improve the health of long-term survivors will be described, and the growing focus on the provision of optimal long-term follow-up care and the quality of survivorship will be emphasized.